Bristol-Myers Squibb logo Bristol-Myers Squibb Co (NYSE:BMY) - Analysts at Jefferies Group upped their FY2017 earnings estimates for Bristol-Myers Squibb in a report released on Friday, according to Zacks Investment Research.
Bristol-Myers Squibb logo Bristol-Myers Squibb Co (NYSE:BMY) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday, MarketBeat reports.
Bristol-Myers Squibb logo M. Kraus & Company acquired a new position in Bristol-Myers Squibb Co (NYSE:BMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Berenberg upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Hold to Buy with a price target of $77. Analyst Laura Sutcliffe said Bristol-Myers is in a very good place to deliver strong growth in the medium term.
Whole Foods Market, Inc. (NASDAQ: WFM) shares have lost 12 percent since December 28, while shares of Bristol-Myers Squibb Co (NYSE: BMY) are down 7 percent. BMO Capital Markets analysts downgraded the ratings and reduced the price targets of ...
Bristol-Myers Squibb Company (NYSE:BMY) has reserved a top momentum style rating from Zacks Research. The momentum rating acts as an important barometer to show as to when a stock will attain a favourable position, which will provide a window of ...
As it reflects the theoretical cost of buying the company's shares, the market cap of Bristol-Myers Squibb Company (NYSE:BMY) is currently rolling at 101298.57, making it one of the key stocks in today's market.